Note 22:

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss

Additional information on Revenues:

Major customers:

BARDA contributed 56%, 51% and 76% of the Company’s total revenues in 2023, 2022 and 2021 respectively. Vericel contributed 4% and 28% of the Company’s total revenues in 2023 and 2022 respectively. MTEC contributed 10% and 2.8% of the Company’s total revenues in 2023 and 2022 respectively (see also Note 18).

No other customer contributed 10% or more of the Company’s revenues in 2023, 2022 and 2021.

Geographic information:

The revenues reported in the financial statements are based on the location of the customers, as follows:

	Year ended December 31
	2023		2022		2021

USA (see also Note 18a, 18b, 18c)		13,078		21,872		18,102
EU and other international markets		5,608		4,624		5,661

		18,686		26,496		23,763

Cost of Revenues:

Cost of Revenues from sale of products

	Year ended December 31
	2023			2022			2021

Salary and benefits (including share-based compensation)		2,703			1,828			2,047
Subcontractors		230			58			190
Depreciation and amortization		672			426			559
Cost of materials		916			636			1,039
Other manufacturing expenses		1,207			779			906
Decrease (increase) in inventory of finished products		(801	)		(543	)		242

		4,927			3,184			4,983

Cost of Revenues from development services

	Year ended December 31
	2023		2022		2021

Salary and benefits		1,995		1,691		2,003
Subcontractors		8,182		8,138		7,904

		10,177		9,829		9,907

Cost of Revenues from license agreements

	Year ended December 31
	2023		2022		2021

Salary and benefits		4		38		102
Royalties payments		-		280		-

		4		318		102

Total Cost of Revenues		15,108		13,331		14,992

Research and development expenses:

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation) (1)		3,148		4,494		2,864
Subcontractors		2,833		4,054		6,323
Depreciation and amortization		396		571		396
Cost of materials		785		572		347
Other research and development expenses		305		490		326

Total Research and development		7,467		10,181		10,256

(1)

The salary costs for the year ended December 31,2022 includes one-time payment of $205 derived from termination agreement with the CMO of the company.

Selling and marketing expenses:

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation)		1,991		1,637		1,643
Marketing and consulting		1,637		1,152		627
Depreciation and amortization		50		49		44
Shipping and delivery		356		385		490
Registration and marketing license fees		810		502		584

		4,844		3,725		3,388

General and administrative expenses:

	Year ended December 31
	2023		2022		2021
Salary and benefits (including share‑based compensation)		3,521		3,344		2,905
Professional fees		2,189		2,589		2,480
Depreciation and amortization		185		225		239
Other		873		762		724

		6,768		6,920		6,348

Other (income) expenses:

The other one-time income amounted $211 for the year ended December 31, 2023, is associated with the termination of sub-lease agreement (see note 11a).

The other one-time expenses amounted $684 for the year ended December 31, 2022, are associated with the management changes and FDA milestone payment fee (see Note 18b).

Financial income and expense:

	Year ended December 31
	2023		2022			2021
Financial income:

Interest income		2,341		270			11
Revaluation of liabilities in respect of IIA grants		-		132			-
Revaluation of Warrants		8,310		-			-
Exchange differences, net		-		59			-

		10,651		461			11
Financial expense:

Revaluation of liabilities in respect of IIA grants		427		-			903
Financing income on net investment in lease		274		102			120
Finance expenses in respect of deferred revenues		8		54			143
Revaluation of liabilities in respect of TEVA		468		533			590
Exchange differences, net		654		-			511
Revaluation of Warrants		-		8,977			-
Issuance expenses of warrants through profit and loss		-		1,911			-
Other		61		60			47

		1,892		11,637			2,314

Financial income (expenses), net		8,759		(11,176	)		(2,303	)